Actualité

Dernieres Publications
[18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study
Patient and physician expectation’s regarding disease and treatment of advanced HCC: the prospective PERCEPTION1 study
Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC
Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab.
No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC.
Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: a multicentric retrospective study
[18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study
Patient and physician expectation’s regarding disease and treatment of advanced HCC: the prospective PERCEPTION1 study
Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC
Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab.
No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC.
Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: a multicentric retrospective study

Nos dernières publications
[18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study
Patient and physician expectation’s regarding disease and treatment of advanced HCC: the prospective PERCEPTION1 study
Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC
Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab.
No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC.
Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: a multicentric retrospective study
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What’s new 12 months later?
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area
Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma

Nos derniers essais cliniques

CAPRIH : début en 2024

Cohorte institutionnelle. Cohorte multicentrique chez les patients ayant un cancer primiti hépatique rare Investigateur principal:...

IMMUNO-TH : début en 2024

Essai institutionnel Étude multicentrique ouverte de phase 2 testant l’atezolizumab bevacizumab après récidive d’un CHC...

Nos dernières rencontres

Journée du 18 décembre 2025

Description
Journée du PLCG du 18 décembre 2025
le programme
En savoir plus ...
Date: 2025-12-18
Lieu: Hôpital Saint-Antoine

Journée soutenue par:

Journée du 19 juin 2025

Description
Paris Liver Cancer Group et le consor3um Européen GENIAL Gene environnement interac-on in alcohol-related hepatocellular carcinoma
le programme
En savoir plus ...
Date: 2025-06-19
Lieu: Hôpital Saint-Antoine

Journée soutenue par:

Pour les patients

Découvrez notre encyclopédie d’articles sur différents cas médicaux

explication pédagogique sur les maladies et les traitements

Newsletter

Restez informé des dernières nouvelles

Contactez nous

  • Paris, France
  • contact@parislivercancergroup.com
Pour les patients

Fermer